Skip to main content
Premium Trial:

Request an Annual Quote

Seeking 'Final Plan of Exit' for Array Business, Nanogen Starts Cutting Staff

NEW YORK (GenomeWeb News) - On the heels of Monday’s news that Nanogen is looking to sell, shut down, or find a partner for its microarray business, the company said today in a filing with the US Securities and Exchange Commission that it plans to trim its microarray workforce by 13 staffers, or around four percent.
Those staffers will be handed pink slips immediately, and Nanogen said more employee cuts may be on the way, depending on what the company decides will be its “final plan of exit,” the company said in the filing. 
This round of cuts will cost Nanogen around $335,000 in severance and related expenses.
Nanogen said Monday it wants to divest its microarray segment, which includes the NanoChip product line, in order to cut costs and focus on pursuing its clinical diagnostics strategy.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.